| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/MDS.26331 |
| P698 | PubMed publication ID | 26226924 |
| P2093 | author name string | Avram Fraint | |
| Kathleen M Shannon | |||
| P2860 | cites work | Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase | Q24548047 |
| Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology | Q24621818 | ||
| Treatment of Huntington's disease | Q26782004 | ||
| A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. | Q27860836 | ||
| Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease | Q28202050 | ||
| Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease | Q28261987 | ||
| Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes | Q28302701 | ||
| An International Survey-based Algorithm for the Pharmacologic Treatment of Irritability in Huntington's Disease | Q28476789 | ||
| An International Survey-based Algorithm for the Pharmacologic Treatment of Chorea in Huntington's Disease | Q28476791 | ||
| Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6/2 mouse model of Huntington's disease | Q28488296 | ||
| The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington's disease | Q28705237 | ||
| Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease | Q28748849 | ||
| Mutant huntingtin fragments form oligomers in a polyglutamine length-dependent manner in vitro and in vivo | Q30494325 | ||
| Ganglioside GM1 induces phosphorylation of mutant huntingtin and restores normal motor behavior in Huntington disease mice | Q30506469 | ||
| Quadruple deep brain stimulation in Huntington's disease, targeting pallidum and subthalamic nucleus: case report and review of the literature | Q30793310 | ||
| Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery: a long-term follow-up study | Q33994217 | ||
| Ceftriaxone-induced up-regulation of cortical and striatal GLT1 in the R6/2 model of Huntington's disease | Q34053585 | ||
| Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin | Q34221351 | ||
| Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's disease | Q34330172 | ||
| BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice | Q34338809 | ||
| Targets for future clinical trials in Huntington's disease: what's in the pipeline? | Q34435001 | ||
| Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial | Q34451729 | ||
| Brief ampakine treatments slow the progression of Huntington's disease phenotypes in R6/2 mice | Q34459323 | ||
| A futility study of minocycline in Huntington's disease | Q34622616 | ||
| External globus pallidus stimulation modulates brain connectivity in Huntington's disease | Q34627479 | ||
| A monoclonal antibody TrkB receptor agonist as a potential therapeutic for Huntington's disease | Q35087700 | ||
| Constitutive upregulation of chaperone-mediated autophagy in Huntington's disease | Q35767283 | ||
| Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination | Q36174480 | ||
| Levodopa responsive parkinsonism in an adult with Huntington's disease | Q36318912 | ||
| Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice | Q36389503 | ||
| Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntington's disease mice: implications for the ubiquitin-proteasomal and autophagy systems. | Q36435854 | ||
| Transcriptional signatures in Huntington's disease | Q36752799 | ||
| Role of brain-derived neurotrophic factor in Huntington's disease | Q36767260 | ||
| Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington's disease | Q37120339 | ||
| Symptomatic treatment of Huntington disease | Q37131233 | ||
| Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies | Q37219529 | ||
| A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease | Q37345118 | ||
| PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease | Q37648786 | ||
| Results of the citalopram to enhance cognition in Huntington disease trial | Q37649788 | ||
| Dopamine and glutamate in Huntington's disease: A balancing act. | Q37734563 | ||
| Dysregulation of synaptic proteins, dendritic spine abnormalities and pathological plasticity of synapses as experience-dependent mediators of cognitive and psychiatric symptoms in Huntington's disease. | Q38013453 | ||
| Pharmacological treatment of chorea in Huntington's disease-good clinical practice versus evidence-based guideline | Q38106927 | ||
| Acetylcholinesterase inhibitors in cognitive impairment in Huntington's disease: A brief review | Q38164337 | ||
| The fate of cell grafts for the treatment of Huntington's disease: the post-mortem evidence. | Q38168592 | ||
| The role of oxidative stress in Huntington's disease: are antioxidants good therapeutic candidates? | Q38178744 | ||
| The role of dopamine in Huntington's disease | Q38223504 | ||
| Current therapeutic options for Huntington's disease: good clinical practice versus evidence-based approaches? | Q38244078 | ||
| Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease | Q38345839 | ||
| Deep brain stimulation in Huntington's disease: assessment of potential targets | Q38362441 | ||
| Overexpression of BDNF and Full-Length TrkB Receptor Ameliorate Striatal Neural Survival in Huntington's Disease. | Q38884136 | ||
| Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle | Q39035584 | ||
| Modulation of mutant huntingtin N-terminal cleavage and its effect on aggregation and cell death. | Q39626047 | ||
| Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease | Q39795092 | ||
| Mutant huntingtin interacts with {beta}-tubulin and disrupts vesicular transport and insulin secretion | Q39821495 | ||
| Mutant huntingtin N-terminal fragments of specific size mediate aggregation and toxicity in neuronal cells | Q39885698 | ||
| Cystamine and cysteamine prevent 3-NP-induced mitochondrial depolarization of Huntington's disease knock-in striatal cells | Q40290417 | ||
| Soluble N-terminal fragment of mutant Huntingtin protein impairs mitochondrial axonal transport in cultured hippocampal neurons | Q41457916 | ||
| Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: possible role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in the pathogenesis of Huntington disease | Q42434605 | ||
| P38 MAPK is involved in enhanced NMDA receptor-dependent excitotoxicity in YAC transgenic mouse model of Huntington disease | Q42499525 | ||
| Progressive axonal transport and synaptic protein changes correlate with behavioral and neuropathological abnormalities in the heterozygous Q175 KI mouse model of Huntington's disease | Q44186888 | ||
| Paroxetine retards disease onset and progression in Huntingtin mutant mice | Q44817609 | ||
| Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach | Q44872348 | ||
| The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease | Q45015073 | ||
| Minocycline in phenotypic models of Huntington's disease | Q45223354 | ||
| cAMP-response element-binding protein contributes to suppression of the A2A adenosine receptor promoter by mutant Huntingtin with expanded polyglutamine residues | Q45250028 | ||
| A study of chorea after tetrabenazine withdrawal in patients with Huntington disease | Q45289736 | ||
| A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease | Q45292205 | ||
| In vivo evidence for NMDA receptor-mediated excitotoxicity in a murine genetic model of Huntington disease. | Q45293042 | ||
| Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins. | Q45293052 | ||
| Bilateral globus pallidus stimulation in Westphal variant of huntington disease | Q45294978 | ||
| A 5-year follow-up of deep brain stimulation in Huntington's disease. | Q45296224 | ||
| Deep brain stimulation for Huntington's disease: long-term results of a prospective open-label study. | Q45298634 | ||
| Mutant huntingtin is present in neuronal grafts in Huntington disease patients | Q45299114 | ||
| Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington's disease. | Q45301079 | ||
| Chronic cannabinoid receptor stimulation selectively prevents motor impairments in a mouse model of Huntington's disease | Q45301104 | ||
| Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models | Q45302072 | ||
| A phase II, open-label evaluation of cysteamine tolerability in patients with Huntington's disease. | Q45303127 | ||
| 4-hydroxy tempo improves mitochondrial and neurobehavioral deficits in experimental model of Huntington's disease. | Q45303159 | ||
| A randomized, placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington's disease | Q45304326 | ||
| Pramipexole ameliorates neurologic and psychiatric symptoms in a Westphal variant of Huntington's disease | Q45305349 | ||
| Targeting neuro-inflammatory cytokines and oxidative stress by minocycline attenuates quinolinic-acid-induced Huntington's disease-like symptoms in rats | Q45306608 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Huntington's disease | Q190564 |
| P304 | page(s) | 1539-1546 | |
| P577 | publication date | 2015-07-30 | |
| P1433 | published in | Movement Disorders | Q1486418 |
| P1476 | title | Therapeutic advances in Huntington's Disease | |
| P478 | volume | 30 |
| Q39198759 | A Systematic Review of the Huntington Disease-Like 2 Phenotype |
| Q51744369 | A novel ex vivo Huntington's disease model for studying GABAergic neurons and cell grafts by laser microdissection. |
| Q40848200 | An enhanced Q175 knock-in mouse model of Huntington disease with higher mutant huntingtin levels and accelerated disease phenotypes |
| Q50050416 | Correction of Huntington's Disease Phenotype by Genistein-Induced Autophagy in the Cellular Model |
| Q60956248 | Effect of Coenzyme Q Supplementation on Testosterone |
| Q41187089 | Elimination of huntingtin in the adult mouse leads to progressive behavioral deficits, bilateral thalamic calcification, and altered brain iron homeostasis. |
| Q47277130 | Emotion Recognition Correlates With Social-Neuropsychiatric Dysfunction in Huntington's Disease. |
| Q92238405 | Genistein induces degradation of mutant huntingtin in fibroblasts from Huntington's disease patients |
| Q38805973 | Huntington disease: a single-gene degenerative disorder of the striatum |
| Q39190617 | Huntington's Disease-Update on Treatments |
| Q42705378 | Increased irritability, anxiety, and immune reactivity in transgenic Huntington's disease monkeys |
| Q37652595 | Induced Pluripotent Stem Cells in Huntington's Disease: Disease Modeling and the Potential for Cell-Based Therapy |
| Q52430483 | Inhibition of TRPC1-Dependent Store-Operated Calcium Entry Improves Synaptic Stability and Motor Performance in a Mouse Model of Huntington's Disease. |
| Q39031769 | Investigational agents for the management of Huntington's disease |
| Q28386769 | Mitochondrial targeting of XJB-5-131 attenuates or improves pathophysiology in HdhQ150 animals with well-developed disease phenotypes |
| Q36846550 | Post-mortem Findings in Huntington's Deep Brain Stimulation: A Moving Target Due to Atrophy |
| Q47974512 | Progress in developing transgenic monkey model for Huntington's disease |
| Q38865495 | Prospective Evaluation of Predictive DNA Testing for Huntington's Disease in a Large German Center. |
| Q46299650 | Role of PDE9 in Cognition |
| Q26764930 | The P42 peptide and Peptide-based therapies for Huntington's disease |
| Q28072937 | The chicken or the egg: mitochondrial dysfunction as a cause or consequence of toxicity in Huntington's disease |
| Q53716390 | Therapy development in Huntington disease: From current strategies to emerging opportunities. |
Search more.